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Background: Topiramate is a drug which emerged from its anticonvulsant properties and now over the years is
used for a wider range of indications, including migraine prophylaxis. We described a very rare case of topiramate
induced acute onset myopia during use for migraine. It is the first reported case of its kind from Sri Lanka with only
a handful of reported cases in world literature.
Case presentation: A 35-year-old Sri Lankan female presented with long standing history of intermittent headache
with recent worsening. A diagnosis of migraine was made and due to poor response to other medication was
initiated on topiramate. Two weeks later patient developed visual impairment which was finally attributed to
topiramate. Following discontinuation of the drug, within 3 days the symptoms started to improve with full recovery
in 10 days.
Conclusion: All clinicians should be aware of the potential ocular side effects of topiramate. Although relatively rare,
prompt recognition is key to appropriate management.
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Topiramate (TPM) emerged from its anticonvulsant prop-
erties and now is recommended as a first line medication
in some seizure disorders. Over the years its use has sig-
nificantly increased and is used for a wide spectrum of
other indications including migraine prophylaxis.
Topiramate is a sulfa-derivative monosaccharide with
several mechanisms of action, mainly including blockage
of voltage-gated sodium channels, hyperpolarization and
enhancement of postsynaptic gamma-aminobutyric acid
receptor activity [1]. It is a drug with numerous side ef-
fects, in particular ophthalmologic side effects [2]. Due
to increased use it is prudent that the clinician is fully
aware of these potential side effects. We describe here a
rare case of topiramate induced acute onset myopia. The
author feels it is the first reported case of its kind
from Sri Lanka despite having reported cases in world
literature [3].* Correspondence: rajithaasa55@gmail.com
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A 35-year-old Sri Lankan female with long standing inter-
mittent headaches presented with recent worsening of
headache. Clinical examination performed by the phys-
ician revealed normal neurological examination and vision
with a visual acuity of 6/6 without any correction. A
provisional diagnosis of migraine has been made on a pre-
vious occasion and she had been commenced on multiple
medications over a period of time including propranolol
and flunarazine. This had helped initially, but not in the
long term.
The patient was reassured and asked to continue flu-
narazine. She presented one month later with no relief
from her headaches. Examination was unremarkable. Flu-
narazine was discontinued and she was commenced on
topiramate 25 mg at night.
2 weeks later she complained of acute onset blurring
of vision. There were no other neurological symptoms.
An ophthalmological consultation revealed no significant
visual finding except for a bilateral refractive error of –
0.5 diopters. Her visual symptoms persisted to the next
day, but did not worsen. Suspecting topiramate induced
myopia the drug was discontinued and the patient wastral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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acuity of 6/6, normal intraocular pressure and a worsen-
ing of refractive error to −3.5 diopters bilaterally. On the
3rd day following discontinuation of topiramate her vis-
ual symptoms started to improve and at the end of
10 days her vision was back to normal with no evidence
of a refractive error (0 diopters).
A diagnosis of topiramate induced acute myopia was
made. An ophthalmologist review 2 weeks later was normal.
Discussion
This patient had no other previous medical illness or
visual disorders prior to the commencement of topira-
mate. The symptom onset was very acute in nature fol-
lowing commencement of topiramate and improved
spontaneously on discontinuation of the drug.
The exact mechanism by which TPM and other sulfa
derivatives initially triggers myopia is not completely
understood. However, to date, a number of mechanisms
have been suggested as possible triggers.
One of the earliest hypotheses was proposed by Sen et
al. [4]. They suggested that the entry of TPM into the
lens alters its osmotic status, causing it to swell and, con-
sequently, resulting in angle closure glaucoma (ACG) and
myopia. Another hypothesis by Ikeda et al. [5] in 2002 led
to the origin of the clinical entity “Ciliochoroidal effusion
syndrome” which can be defined as a spectrum of clinical
manifestations ranging from transient topiramate in-
duced myopia to severe bilateral ACG . These compli-
cations were attributed to ciliochoroidal effusion and
swelling of the ciliary body, which can potentially re-
sult in anterior rotation of the ciliary processes, causing
narrowing of the ciliary sulcus and forward displacement
of the iris and lens.
Another theory is that Ciliochoroidal effusion syn-
drome is due to an idiosyncratic reaction. This compli-
cation occurring in a small proportion and some studies
showing no correlation between TPM dosage with the
level of intra ocular pressure or myopia supports this.
Patients with topiramate induced myopia often com-
plain of sudden blurred vision. The symptoms are docu-
mented to occur within the first 2 weeks after drug
initiation. As the mean plasma elimination half life of
the drug is about 21 hours, rapid visual recovery usually
occurs although in some cases it can take several weeks.
In the management of topiramate induced myopia, the
most important measure is to discontinue TPM and seek
urgent ophthalmology opinion. In the long term an al-
ternative agent should be used.
Conclusion
Ocular examination before starting topiramate cannot
identify eyes at risk. Patients commencing topiramate
should therefore be advised to immediately report anysymptoms of eye pain or blurred vision especially in the
first few weeks of treatment.
All clinicians involved in the management of the pa-
tient including the physician, neurologist and ophthal-
mologists need to be aware of the potential ocular side
effects of topiramate. Although relatively rare, prompt
recognition is key so appropriate management can be in-
stituted and visual outcomes minimized.
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